Immunome Quote - IMNM | ADVFN

S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Immunome Inc (IMNM) Share Price

Immunome Inc (IMNM)

12.10

0.13

(1.09%)

Closed June 28 3:00PM

Delayed by 15 minutes

12.02

-0.08

( -0.66% )

Pre Market: 3:21AM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Current Price

12.02

Bid

12.00

Ask

13.47

Volume

300

0.00 Day's Range 0.00

6.13 52 Week Range 30.958

Market Cap

Previous Close

12.10

Open

-

Last Trade

Last Trade Time

03:21:17

Financial Volume

-

VWAP

-

Average Volume (3m)

1,035,462

Shares Outstanding

59,968,868

Dividend Yield

-

PE Ratio

-6.79

Earnings Per Share (EPS)

-1.78

Revenue

14.02M

Net Profit

-106.81M

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.immunome.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Immunome Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNM. The last closing price for Immunome was US$12.10. Over the last year, Immunome shares have traded in a share price range of US$ 6.13 to US$ 30.958.

Immunome currently has 59,968,868 shares outstanding. The market capitalization of Immunome is US$725.62 million. Immunome has a price to earnings ratio (PE ratio) of -6.79.

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.41	-3.29847144006	12.43	12.51	11.07	2597681	12.02409996	CS
4	-2.98	-19.8666666667	15	16.58	11.07	1436536	13.0491547	CS
12	-8.29	-40.8173313639	20.31	21.72	11.07	1035462	14.3512855	CS
26	1.22	11.2962962963	10.8	30.958	10.38	859732	17.48298152	CS
52	4.11	51.9595448799	7.91	30.958	6.13	481027	16.46021146	CS
156	-5.31	-30.64050779	17.33	30.958	2.09	249979	15.13996338	CS
260	-3.64	-23.2439335888	15.66	63.78	2.09	228869	16.83601751	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DNDelta 9 Cannabis Inc	$ 0.015 (50.00%)	1.1M
BRMIBoat Rocker Media Inc	$ 1.02 (29.11%)	1.84M
TSATTelesat Corporation	$ 12.50 (17.26%)	3.24k
QECQuesterre Energy Corporation	$ 0.25 (16.28%)	24.6k
GEOGeodrill Limited	$ 2.30 (15.58%)	47.28k
NCPNickel Creek Platinum Corp	$ 0.01 (-33.33%)	1.07k
LPENLoop Energy Inc	$ 0.025 (-28.57%)	73.62k
ASNDAscendant Resources Inc	$ 0.035 (-22.22%)	1,000
FLNTFlint Corporation	$ 0.025 (-16.67%)	16.5k
BNGBengal Energy Ltd	$ 0.03 (-14.29%)	85k
TRPTC Energy Corporation	$ 51.87 (-1.76%)	34.35M
BNSBank of Nova Scotia	$ 62.58 (0.29%)	18.9M
POWPower Corp of Canada	$ 38.02 (-1.66%)	13.19M
TDToronto Dominion Bank	$ 75.20 (0.09%)	9.87M
MFCManulife Financial Corporation	$ 36.44 (0.41%)	6.48M

Monksdream

Monksdream 3 months ago

IMNM 10Q due 3/22

Monksdream

Monksdream 4 months ago

IMNM new 52 week hi

Monksdream

Monksdream 6 months ago

IMNM new 52 week high

OncoJock

OncoJock 7 months ago

Agree.

Wish there were most posts on this board.

Wondering who might be the next big customer to sign a major discovery and commercialization contract with IMNM, after AbbVie?

Also wondering if IMNM is doing any discovery/testing/research related to bispecific antibodies, as opposed to antibody-drug conjugates. Bispecifics are HOT HOT HOT in lymphoma and myeloma.

-- OJ

OncoJock

OncoJock 7 months ago

Laster

Laster 9 months ago

Hopefully the vote passed.
I think this biotech combined company can be a huge success.
Siegall has proven he can build a biotech company.
This will be fun to watch.

Laster

Laster 9 months ago

I believe merger news tomorrow along with huge financing.
Clay B. Siegall To become chairman and CEO of combined company.
He founded Seagen which just sold for $40 billion to Pfizer.
Their innovative technology from Professor Philip S. Low (Purdue University).
Look at Professor Low accomplishments. Unreal.
Watching closely because this might become a huge biotech company.

wiwineguy

wiwineguy 1 year ago

Ha, sold in fall of 21 for $25.

makinezmoney

makinezmoney 1 year ago

$IMNM: Now 10.40 !!!!!!!!!!!

Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

GO $IMNM

makinezmoney

makinezmoney 1 year ago

$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50

Offfffffffffff she goes.

Nice boomer

GO $IMNM

Awl416

Awl416 1 year ago

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

wiwineguy

wiwineguy 3 years ago

you don't know crap majorbankz. you keep saying i "heard" this, and I "heard" that. can you be any more vague. stfu

Harbor6460

Harbor6460 3 years ago

They cannot dilute on the bid. Only the ask

Pedro2004

Pedro2004 3 years ago

Pulled down to under $20.00

Pedro2004

Pedro2004 3 years ago

They pulled this down to under $21.00

I'm back-in at $21.00

Major_Bankz

Major_Bankz 3 years ago

$22.50 U worry too much, should be $25+ this afternoon IMO

Pedro2004

Pedro2004 3 years ago

I thought this was going to break today. But it' just jumped over $22 -- let's see if that holds.

Pedro2004

Pedro2004 3 years ago

This run could have broke $30 today. But the company killed-it.

Major_Bankz

Major_Bankz 3 years ago

yep, shorties portfolio will get destroyed here.

Pedro2004

Pedro2004 3 years ago

The dilution is going to kill this run.

Pedro2004

Pedro2004 3 years ago

Looks like the company is dumping shares on the bid.

Major_Bankz

Major_Bankz 3 years ago

I don't think PFE and MRNA can claim the same effectiveness for DELTA, plus time to buy is during development not after just like when MRNA was at $20. IMO

Major_Bankz

Major_Bankz 3 years ago

Delta is a BIG problem, IMNM may catch up to PFE and MRNA. IMO

Major_Bankz

Major_Bankz 3 years ago

Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.

Major_Bankz

Major_Bankz 3 years ago

IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions